Abstract
Treatment with a BRAF and MEK inhibitor can achieve a sustained response in BRAF(V600)-mutant Langerhans cell histiocytosis. Detection of plasma BRAF(V600)-mutant circulating tumor DNA is a promising biomarker for monitoring disease activity in this entity.